Background
Methods
Design
Data collection
Statistics
Results
Clinical characteristics of DAH
All patients (n = 104) | Connective tissue disorder (n = 25) | Vasculitis (n = 79) | p | |
---|---|---|---|---|
A. Baseline characteristics | ||||
Demographics | ||||
Age, years, median [IQR] | 56 [32–68] | 42 [27–55] | 61 [39–71] | 0.003 |
Male gender, n (%) | 56 (54%) | 7 (29%) | 48 (61%) | 0.02 |
Comorbidities | ||||
Charlson score, median [IQR] | 3 [1–4] | 2 [1–3.5] | 3 [1–4] | 0.23 |
Previous steroid treatment, n (%) | 26 (25%) | 10 (40%) | 16 (20%) | 0.064 |
Systemic disease,n(%) | ||||
Connective tissue disorder | 25 (24%) | NA | NA | |
Systemic lupus erythematosus | 12 (48%) | |||
Primary antiphospholipid syndrome | 9 (36%) | |||
Others* | 4 (16%) | |||
Vasculitis | 79 (76%) | NA | NA | |
ANCA-associated vasculitis | 57 (72%) | |||
Anti-GBM disease | 12 (15%) | |||
Cryoglobulin-associated vasculitis | 4 (5%) | |||
IgA-associated vasculitis | 6 (8%) | |||
Inaugural | 76 (73%) | 13 (52%) | 63 (80%) | 0.01 |
Relapse | 28 (27%) | 12 (48%) | 16 (20%) | |
Systemic disease manifestations, n (%) | ||||
DAH | 104 (100%) | 25 (100%) | 79 (100%) | 1 |
Hemoptysis | 53 (51%) | 10 (40%) | 43 (54%) | 0.25 |
Cough | 68 (65%) | 17 (68%) | 51 (65%) | 0.81 |
Acute respiratory failure | 78 (75%) | 20 (80%) | 58 (73%) | 0.6 |
Renal | 83 (81%) | 14 (56%) | 69 (89%) | 0.0009 |
Digestive | 7 (7%) | 2 (8%) | 5 (6%) | 0.68 |
Nervous system | 16 (16%) | 6 (24%) | 10 (13%) | 0.21 |
Joint | 20 (19%) | 4 (16%) | 16 (21%) | 0.78 |
Skin | 23 (22%) | 7 (28%) | 16 (21%) | 0.42 |
ICU admission characteristics, median [IQR] | ||||
SAPS II | 36 [25.75–47] | 33 [26–42] | 38 [26–48] | 0.51 |
Temperature | 37.9 [37–38.6] | 38.2 [37.2–39.1] | 37.7 [37–38.5] | 0.15 |
Oxygen flow, L/min | 15 [5–15] | 12 [5–15] | 15 [5–15] | 0.92 |
PaO2/FiO2 ratio | 150 [87–229] | 120 [90–230] | 157 [86–225] | 0.64 |
Time (days) from dyspnea onset to ICU admission | 5 [1–21] | 1 [0–10] | 6 [1–24] | 0.018 |
Time (days) from first symptoms to ICU admission | 30 [11.8–79] | 17 [10–46] | 32 [15–88] | 0.079 |
Time (days) from hospital admission to ICU admission | 5 [1–12] | 7 [3–15] | 3 [0–12] | 0.13 |
Biological findings at ICU admission, median [IQR] | ||||
Hemoglobin, g/L | 86 [72–95] | 87 [75–97] | 86 [72–95] | 0.73 |
Leukocytes, G/L | 11.7 [8.9–15.6] | 11.1 [6.4–17.1] | 11.7 [9.2–15.4] | 0.47 |
Platelets count, G/L | 257 [141–353] | 102 [53–236] | 278 [186–401] | < 0.0001 |
Creatinine, μmol/L | 235 [92–433] | 103 [71–174] | 303 [128–520] | 0.0002 |
Urine protein/creatinine, g/mmol | 0.19 [0.1–0.33] | 0.12 [0.07–0.25] | 0.2 [0.1–0.34] | 0.17 |
LDH, mmol/L | 488 [354–905] | 873 [532–1152] | 454 [329–714] | 0.008 |
B. ICU management. | ||||
ICU management,n(%) | ||||
Vasopressor use | 36 (35%) | 8 (32%) | 28 (35%) | 0.81 |
Renal replacement therapy | 55 (53%) | 6 (24%) | 49 (62%) | 0.001 |
Respiratory management | ||||
Non-invasive ventilation | 33 (32%) | 8 (32%) | 25 (32%) | 1 |
Mechanical ventilation | 52 (50%) | 11 (44%) | 41 (52%) | 0.65 |
ARDS diagnosis | 52 (50%) | 13 (52%) | 43 (55%) | 0.82 |
Prone positioning | 11 (21%) | 3 (12%) | 8 (11%) | 1 |
Mechanical ventilation duration, days, median [IQR] | 12 [6–22] | 4 [4–18] | 13 [9–33] | 0.007 |
Red blood cell transfusion | 78 (75%) | 16 (64%) | 62 (80%) | 0.33 |
Systemic disease management,n(%) | ||||
Time (days) from first symptoms to diagnosis | 31 [11.5–77] | 19.5 [10–53] | 32 [15–86] | 0.14 |
Steroids | 103 (99%) | 25 (100%) | 78 (99%) | 1 |
Steroids pulse therapy | 93 (89%) | 20 (80%) | 73 (92%) | 0.13 |
Cyclophosphamide | 72 (69%) | 9 (36%) | 63 (80%) | < 0.0001 |
Rituximab | 12 (11.5%) | 1 (4%) | 11 (14%) | 0.29 |
PLEX | 57 (55%) | 6 (24%) | 51 (65%) | 0.0009 |
Number of PLEX | 7 [4.3–9.5] | 4 [2–9] | 7 [5–9] | 0.32 |
Bacterial superinfection,n(%) | 30 (29%) | 3 (12%) | 27 (34%) | 0.042 |
Hospital mortality,n(%) | 16 (15%) | 3 (12%) | 13 (17%) | 0.76 |
Follow-up | 48 (55%) | 13 (59%) | 35 (53%) | 0.65 |
Length of follow-up (months) | 19 [8–38] | 37 [11–66] | 15 [7–28] | 0.003 |
Chronic renal failure** | 22 (65%) | 4 (80%) | 18 (62%) | 0.33 |
Dialysis** | 8 (24%) | 1 (20%) | 7 (24%) | 0.42 |
Comparison between patients with connective tissue disorder and vasculitis
Invasive mechanical ventilation requirement, weaning, and ICU management
Parameters | No invasive ventilation n = 52 | Invasive ventilation n = 52 | p value |
---|---|---|---|
Age, years, median [IQR] | 50 [29–62] | 58 [39–70] | 0.12 |
Charlson comorbidity index, median [IQR] | 3 [1.3–4.8] | 3 [1–4] | 0.59 |
Vasculitis, yes, n (%) | 38 (73%) | 41 (79%) | 0.65 |
Hemoptysis, yes, n (%) | 30 (58%) | 23 (44%) | 0.24 |
Acute respiratory failure, n (%) | 28 (54%) | 50 (96%) | < 0.0001 |
Renal involvement, yes, n (%) | 40 (77%) | 43 (84%) | 0.46 |
SAPS II, median [IQR] | 29 [19–37] | 44 [33–56] | < 0.0001 |
PaO2/FiO2 ratio, median [IQR] | 205 [123–263] | 108 [75–190] | 0.0003 |
Time (days) from dyspnea to ICU admission, days, median [IQR] | 6 [1–23] | 5 [1–16] | 0.70 |
Hemoglobin at day 1, median [IQR] | 8.3 [7.4–9.5] | 8.6 [7.2–9.5] | 0.85 |
Neutrophil count at day 1, median [IQR] | 8.2 [6.4–10.2] | 10.6 [7.6–18.0] | 0.05 |
LDH at day 1, UI/L, median[IQR] | 432 [317–626] | 679 [409–1213] | 0.010 |
Factors associated with ICU survival
Parameter | Univariate analysis | |
---|---|---|
SHR 95%CI | p value | |
Age (per 10 years) | 0.87 (0.79–0.95) | 0.0016 |
Sex | 1.12 (0.75–1.7) | 0.58 |
Charlson comorbidity index | 0.88 (0.81–0.97) | 0.0078 |
Chronic respiratory failure | 0.73 (0.29–1.82) | 0.49 |
Chronic cardiac failure | 0.34 (0.16–0.74) | 0.0063 |
Chronic renal failure | 0.59 (0.3–1.17) | 0.13 |
Steroid treatment | 0.78 (0.44–1.37) | 0.38 |
Connective tissue disorder | 1.35 (0.82–2.22) | 0.24 |
Systemic lupus | 1.07 (0.48–2.41) | 0.86 |
Antiphospholipid syndrome | 2.26 (1.35–3.78) | 0.0018 |
Other systemic disease | 0.87 (0.36–2.09) | 0.76 |
Vasculitis | 1.35 (0.82–2.22) | 0.24 |
ANCA-associated vasculitis | 0.95 (0.62–1.45) | 0.8 |
Goodpasture syndrome | 1.08 (0.7–1.66) | 0.73 |
Cryoglobulin-associated vasculitis | 0.17 (0.02–1.68) | 0.13 |
IgA-associated vasculitis | 0.49 (0.15–1.6) | 0.24 |
Relapse | 1.07 (0.63–1.81) | 0.81 |
Hemoptysis | 1.18 (0.79–1.77) | 0.42 |
Acute respiratory failure | 0.57 (0.37–0.89) | 0.014 |
Renal involvement | 0.73 (0.46–1.14) | 0.17 |
Digestive involvement | 1.31 (0.45–3.85) | 0.62 |
Nervous system involvement | 1.21 (0.78–1.87) | 0.39 |
Joint involvement | 0.8 (0.48–1.34) | 0.41 |
Skin involvement | 0.81 (0.48–1.36) | 0.43 |
Other systemic disease manifestations | 1.1 (0.93–1.3) | 0.25 |
SAPS II | 0.97 (0.96–0.99) | < 0.0001 |
Oxygen flow | 0.95 (0.91–0.98) | 0.0032 |
PAO2 over FiO2 ratio (per 10 points) | 1.02 (1–1.04) | 0.0099 |
Time (days) from dyspnea onset to ICU admission | (0.98–1) | 0.13 |
Time (days) from hospital admission to ICU admission | 1.01 (0.98–1.04) | 0.6 |
Hemoglobin at ICU admission | 0.97 (0.89–1.05) | 0.41 |
Lymphocytes at ICU admission | 2.51 (1.6–3.95) | < 0.0001 |
Neutrophil count at ICU admission | 1.02 (0.98–1.06) | 0.45 |
Platelets count at ICU admission (per 10G/L) | 1.01 (0.99–1.02) | 0.36 |
Creatinine at ICU admission (per 10 μmol/L) | 1 (0.99–1.01) | 0.72 |
Urine protein/creatinine ratio | 0.97 (0.46–2.02) | 0.93 |
LDH at ICU admission (per 100UI/L) | 0.98 (0.94–1.02) | 0.31 |
Vasopressor use | 0.29 (0.18–0.47) | < 0.0001 |